Hematopoietic stem cell transplantation has been the standard of care for infants with severe combined immunodeficiency (SCID) since 1968, and although the requirement for pretransplant cytoreductive chemotherapy to achieve durable reconstitution has been hotly debated, it is now clear that most SCID genotypes benefit from preparative chemotherapy. However, the requirement for preparative chemotherapy is less clear for interleukin-7 receptor alpha chain (IL-7R alpha) deficiency. In this issue of Blood, Kaiser et al(1) present data on the role of IL-7 signaling in humans that help to clarify this issue.
机构:
Jesse Brown VA Med Ctr, Chicago, IL USA
Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL USAJesse Brown VA Med Ctr, Chicago, IL USA
Meyer, Anja
Parmar, Prashant J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL USAJesse Brown VA Med Ctr, Chicago, IL USA
Parmar, Prashant J.
Shahrara, Shiva
论文数: 0引用数: 0
h-index: 0
机构:
Jesse Brown VA Med Ctr, Chicago, IL USA
Univ Illinois, Dept Med, Div Rheumatol, Chicago, IL USA
Univ Illinois, Dept Med, Div Rheumatol, 840 S Wood St,CSB suite 1114, Chicago, IL 60612 USAJesse Brown VA Med Ctr, Chicago, IL USA
机构:John B. Harley is in the Arthritis and Immunology Program at the Oklahoma Medical Research Foundation,and the US Department of Veterans Affairs Medical Center